Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-01-10
1995-09-12
Gupta, Yogendra N.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540547, 540557, A61K 3155, C07D26720, C07D41312
Patent
active
054496730
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
(1) Field of the Invention
This application is a 371 of PCT/U.S.92/06584, filed on Aug. 13, 1992.
The present invention generally relates to compounds having pharmacological activity which are useful as pharmacological agents and, more particularly, as analgesic agents for the treatment of pain, to pharmaceutical compositions containing one or more of these compounds, and to methods of treatment employing these compounds. More particularly, the present invention concerns substituted dibenzoxazepine compounds, pharmaceutical compositions containing one or more of these compounds in combination with a pharmaceutically-acceptable carrier, and methods of treating pain employing these compounds.
Analgesic compounds are agents which alleviate pain without causing a loss of consciousness and, thus, which are useful for treating pain.
The major classes of analgesic compounds include narcotic analgesics, or opiates, compounds which alleviate pain and induce sleep, and analgesic-antipyretic compounds, compounds which alleviate pain and reduce fever, such as salicylates.
Although the efficacy of opiates in relieving pain is well established, the associated addiction liability of opiates is a distinct disadvantage of these compounds.
While salicylate and salicylate-like agents (non-steroidal antiinflammatory agents or NSAIDS) are also efficacious in relieving pain, they often exhibit undesirable side effects, such as gastrointestinal irritation, as with aspirin, allergic response, as with aspirin, and/or liver toxicity with extended use, as with acetaminophen.
The compounds of the present invention are neither opiates nor NSAIDS, and represent another class of compounds which are useful as analgesic agents.
(2) Description of the Related Art
U.S. Pat. No. 4,290,953 discloses dibenzoxazapine derivatives as-cholesterol lowering agents.
U.S. Pat. Nos. 4,559,336 and 4,614,617 (a continuation-in-part of U.S. 4,559,336) disclose 8-chlorodibenz[b,f][1,4] oxazepine-10(11H)-carboxylic acid, 2-(sulfinyl- and sulfonyl-containing acyl)hydrazides, and intermediates thereof.
U.S. Pat. No. 3,534,019 discloses hydrazides of dibenzoxazepine-, dibenzothiazepine- and dibenzodiazepine-carboxylic acids.
U.S. Pat. No. 3,624,104 discloses aralkanoyl derivatives of dibenzoxazepine-N-carboxylic acid hydrazide compounds.
U.S. Pat. No. 3,989,719 discloses N,N'-diacyl hydrazines.
U.S. Pat. Nos. 3,917,649 and 3,992,375 (a divisional of U.S. Pat. No. 3,917,649) disclose dibenzoxazepine N-carboxylic acid hydrazides compounds.
U.S. Pat. Nos. 4,045,442, 4,125,532 (a divisional of U.S. Pat. No. 4,045,442) and 4,170,593 (a divisional of U.S. Pat. No. 4,125,532) disclose 1(substituted amino)alkanoyl-2-(dibenzoxazepine-10-carbonyl)hydrazides compounds.
U.S. Pat. No. 4,559,337 discloses 8-chlorodibenz-[b,f][1,4]-oxazepine-10(11H)-carboxylic acid, 2-(alkoxy-containing acyl)hydrazide compounds.
GB 1 522 003 discloses 1-acyl-2-(8-chloro-10,11-dihydrodibenz[b,f][1,41oxazepine-10-carbonyl)hydr azine compounds.
GB 1 331 892 discloses derivatives of dibenzoxazepine N-carboxylic acid hydrazides.
European Patent Application Publication No. 0 193 822 discloses 8-chlorodibenz[b,f][1,4]-oxazepine-10(11H)-carboxylic acid, 2-(thio-, sulfinyl- and sulfonyl-containing acyl)hydrazide compounds.
European Patent Application Publication No. 0 218 077 discloses 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2[(substituted phenylsulfinyl)alkanoyl]hydrazide compounds and 8-chlorodibenz-[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(substituted phenylsulfonyl)alkanoyl]hydrazide compounds, and intermediates used in the preparation of these compounds.
Drower et al., "The Antiociceptive Effects of Prostaglandin Antagonists in the Rat," European Journal of Pharmacology, 133, 249-256 (1987), disclose the study of the antinociceptive properties of two competitive antagonists of prostaglandins of the E series, 8-chlorodibenz[b,f][1,4]-oxazepine-10(11H)-carboxylic acid, 2-acetylhydrazide and 8-chlorodibenz[b,f][1,4]-oxazepine-10(11H)-carboxylic
REFERENCES:
patent: 2852528 (1958-09-01), Hoffmann et al.
patent: 3210372 (1965-10-01), Werner et al.
patent: 3357998 (1967-12-01), Cusic et al.
patent: 3534019 (1970-10-01), Coyne et al.
patent: 3624104 (1971-11-01), Cusic et al.
patent: 3917649 (1975-11-01), Mueller
patent: 3989719 (1976-11-01), Mueller
patent: 3992375 (1976-11-01), Mueller
patent: 4045442 (1977-08-01), Mueller
patent: 4125532 (1978-11-01), Mueller
patent: 4170593 (1979-10-01), Mueller
patent: 4290953 (1981-09-01), Koizumi et al.
patent: 4379150 (1983-04-01), Ito et al.
patent: 4559336 (1985-12-01), Mueller
patent: 4559337 (1985-12-01), Mueller
patent: 4614617 (1986-09-01), Mueller
patent: 4681939 (1904-07-01), Mueller
patent: 4704386 (1987-11-01), Mueller
patent: 5180720 (1993-01-01), Husa et al.
patent: 5182272 (1993-01-01), Hallinan et al.
patent: 5212169 (1993-05-01), Husa et al.
patent: 5225417 (1993-07-01), Dappen et al.
patent: 5281590 (1994-01-01), Husa et al.
patent: 5283240 (1994-02-01), Hallinan et al.
patent: 5288719 (1994-02-01), Husa et al.
A. Bennett, et al. "Antagonism of Prostanoid-Induced Contractions of Rat Gastric Fundus Muscle by SC-19220 Sodium Meclofenamate, Indomethacin or Trimethoquinol," Br. J. Pharmac., 71, 169-175 (1980)-London.
W. E. Coyne, et al. "Anticonvulsant Semicarbazides," J. Med. Chem., 11(6), 1158-1160 (1968)-USA.
E. J. Drower, et al. "The Antiociceptive Effects of Prostaglandin Antagonists in the Rat," European Journal of Pharmacology, 133, 249-256 (1987)-Europe.
F. R. George, et al. "Antagonism of Alcohol Hypnosis by Blockade of Prostaglandin Synthesis and Activity: Genotype and Time Course Effects," Pharmacology, Biochemistry & Behavior, vol. 19, 131-136 (1983)-USA.
R. Gimet, et al. "Quantitative Determination of Polymorphic Forms in a Formulation Matrix Using the Near Infra-Red Reflectance Analysis Technique," Journal of Pharmaceutical & Biomedical Analysis, vol. 5, No. 3, 205-211 (1987)-Great Britain.
A. Gomes, et al. "Pharacodynamics of Venom of the Centipede Scolopendra Subspinipes Dehaani," Indian Journal of Experimental Biology, vol. 20, 615-618, Aug. (1982)-India.
K. Gyires, et al. "The Use of the Writhing Test in Mice for Screening Different Types of Analgesics," Arch. Int. Pharmacodyn, 267, 131-140 (1984)-USA.
D. E. MacIntyre, et al. "Antagonism of Human Platelet Responses to Stimulatory and Inhibitory Prostaglandins," Prog. Lipid. Res., 20(1-4), 453-9(1981)-USA.
C. A. Maggi, et al. "The Effect of SC-19220, a Prostaglandin Antagonist, on the Micturition Reflex in Rats," European Journal of Pharmacology, 152, 273-279 (1988)-Europe.
K. Nagarajan, et al. "Synthesis of 10,11-Dihydrodibenz[b,f][1,4]oxazepine Derivatives as Potential Anticonvulsant & Psychotropic Agents," Indian Journal of Chemistry, vol. 24B, 840-844(1985)-India.
S. Nakajyo, et al. "Inhibitory Effect of Bassianolide, a Cyclodepsipeptide, on Drug-Induced Contractions of Isolated Smooth Muscle Preparations," Japan J. Pharmacol., 32, 55-64 (1982)-Japan.
A. Rakovska, et al. "Antagonistic Effect of SC-19220 on the Responses of Guinea-Pig Gastric Muscles to Prostaglandins E.sub.1, E.sub.2, and F.sub.2.alpha.," Arch. Int. Pharmacodyn., 268, 59-69 (1984)-USA.
J. H. Sanner "Dibenzoxazepine Hydrazides as Prostaglandin Antagonists," Intra-Science Chem. Rept., vol. 6, No. 1, 1-9 (1972)-USA.
J. H. Sanner, et al. "Structure-Activity Relationships of Some Dibenzoxazepine Derivatives as Prostaglandin Antagonists," Advances in the Biosciences, 9, 139-148 (1972)-USA.
Chandrakumar Nizal S.
Hagen Timothy J.
Hallinan E. Ann
Husa Robert K.
G. D. Searle & Co.
Gupta Yogendra N.
Hastreiter Roberta L.
Williams Roger A.
LandOfFree
10,11-dihydro-10-(3-substituted-1-oxo-2-propyl, propenyl or prop does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 10,11-dihydro-10-(3-substituted-1-oxo-2-propyl, propenyl or prop, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 10,11-dihydro-10-(3-substituted-1-oxo-2-propyl, propenyl or prop will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-405422